| 12:10-12:20 | 致辞 |
致辞 |
|||||
| 12:20-12:40 | 企业专题会 |
2024年PQCC尿路上皮癌HER2 IHC判读质控结果及病例解析 |
|
||||
| 12:40-13:00 | 企业专题会 |
2024年PQCC尿路上皮癌HER2 IHC染色质控结果及对策 |
|
||||
| 13:00-13:10 | 总结 |
总结 |
|||||
| 14:00-14:25 | 专题发言 |
少见淋巴瘤的病理诊断思路 |
|
||||
| 14:25-14:50 | 专题发言 |
霍奇金淋巴瘤的诊断陷阱 |
|
||||
| 14:50-15:00 | 发言交流 |
327例具有噬血细胞淋巴组织细胞增多症表现的淋巴组织疾病的病理类型构成分析 |
|
||||
| 15:00-15:10 | 发言交流 |
AITL中RHOA非经典突变的分子特征与功能预测 |
|
||||
| 15:10-15:20 | 发言交流 |
ICAM1/ITGAL-Mediated Crosstalk Between EGR1+ B Cells and CXCL13+ CD8+ T Cells Dictates Prognosis and Immunotherapy Efficacy in extranodal NK/T-cell lymphoma |
|
||||
| 15:20-15:30 | 发言交流 |
Proliferation center microenvironmental components represented by Tfh and Treg cells differ between IGHV-mutated and unmutated CLL/SLL |
|
||||
| 15:30-15:40 | 发言交流 |
Temporal Dynamics of Acute Epstein–Barr Virus-Positive T Cell Lymphoid Hyperplasia |
|
||||
| 15:50-16:15 | 专题发言 |
T细胞淋巴瘤病理进展和诊断误区 |
|
||||
| 16:15-16:40 | 专题发言 |
对EBV阳性淋巴组织增殖性疾病的病理认识 |
|
||||
| 16:40-16:50 | 发言交流 |
BCL2假阴性的生发中心来源的非霍奇金B细胞淋巴瘤6例病例报道并文献复习 |
|
||||
| 16:50-17:00 | 发言交流 |
Multi-omics Characterization Reveals Clinicopathological and Molecular Heterogeneity of Primary Gastrointestinal EBV+ Inflammatory Follicular Dendritic Cell Sarcoma:Study of 10 cases |
|
||||
| 17:00-17:10 | 发言交流 |
EB病毒阳性滤泡性淋巴瘤的临床病理特征 |
|
||||
| 17:10-17:20 | 发言交流 |
24例十二指肠型滤泡性淋巴瘤的临床、内镜及病理特征分析 |
|
||||
| 17:20-17:30 | 发言交流 |
原发胸腺黏膜相关淋巴组织结外边缘区淋巴瘤:27例临床病理学特征及预后分析 |
|
||||